Nanobodies targeting the interaction interface of programmed death receptor 1 (PD-1)/PD-1 ligand 1 (PD-1/PD-L1)-Reference-Cited by-同舟云学术

Nanobodies targeting the interaction interface of programmed death receptor 1 (PD-1)/PD-1 ligand 1 (PD-1/PD-L1)

Published:2019-12-04 Issue:3 Volume:50 Page:252-259
ISSN:1082-6068
Container-title:Preparative Biochemistry & Biotechnology
language:en
Short-container-title:Preparative Biochemistry & Biotechnology

Author:

Wen Biyan¹,Zhao Lin¹,Wang Yuchu²,Qiu Chuangnan¹,Xu Zhimin¹,Huang Kunling¹,Zhu He¹,Li Zemin¹,Li Huangjin¹

Affiliation:

1. Guangdong Provincial Key Laboratory of Biotechnology Candidate Drug Research, School of Biosciences and Biopharmaceutics, Guangdong Pharmaceutical University, Guangzhou, Guangdong, P. R. China;

2. School of Chemical Engineering and Light Industry, Guangdong University of Technology, Guangzhou, Guangdong, P. R. China

Publisher

Informa UK Limited

Subject

General Medicine,Biochemistry,Biotechnology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10826068.2019.1692217

Reference30 articles.

1. B7 family checkpoint regulators in immune regulation and disease

2. PD-1 and Its Ligands in Tolerance and Immunity

3. OR.100. PD-L1 Regulates the Development, Maintenance and Function of Induced-regulatory T Cells

4. PD-1/PD-L1, but not PD-1/PD-L2, interactions regulate the severity of experimental autoimmune encephalomyelitis

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advancements in nanobody generation: Integrating conventional, in silico, and machine learning approaches;Biotechnology and Bioengineering;2024-07-25

2. Engineering PD-1-targeted small protein variants for in vitro diagnostics and in vivo PET imaging;Journal of Translational Medicine;2024-05-06

3. Promising Diagnostic and Therapeutic Approaches Based on VHHs for Cancer Management;Cancers;2024-01-15

4. Advances in the structural characterization of complexes of therapeutic antibodies with PD-1 or PD-L1;mAbs;2023-08-02

5. Development of a Functional Nanobody Targeting Programmed Cell Death Protein-1 as Immune Checkpoint Inhibitor;Current Pharmaceutical Design;2023-08